According to a survey by Reuters, Elie Lily’s popular weight loss drug India launch has triggered a large wave of interrogation of the patient about its availability.

Survey of 18 doctors, patients, and weight -loss clinic operators follow the Danish obesity drug rivals Novo Nordisk, followed the market entry of the US drug manufacturer, which expects the second largest population of people suffering from overweight or obesity by 2050.

Suryansh Kumar, founder of Delhi -based Wet Management Services Provider Elevate, said, “Since the launch of Maunzaro, we have seen a significant increase in the customer interest.”

He said in a post on social media that Elevate made more than 200 calls about Maunjaro in just one week.

Mounjaro’s launch has made Indian patients happy who were relying on friends, family or suppliers abroad to catch these drugs.

Vikram, a resident of Bangalore,, a 57 -year -old medical professional, who did not want to publish his nickname to avoid weight stigma, received drugs from Dubai in the last eight months. He has shed more than 23% of his body weight.

“It would now be much more convenient to achieve it,” he said.

Local availability also makes life easier for Indian patients who rely on the black market for weight loss drugs.

Sir HN Reliance Foundation Hospital Director Mufzal Lakdawala said that he hopes that he expects patients who switch to lily’s authorized drug to pay less than half the black market price.

He also hopes that Lily will have an initial-entry benefit on Novo’s vegovi, with its diabetes drug-similar active ingredients, which is often used for weight loss.

“Many of our patients who used to take ozmpic have now changed to take silence due to availability in India,” Lukdavala told Reuters.

‘Wave making’

Novo wants to bring forward the launch of Vagovi’s own planned India to compete better with Lily, two sources told the Reuters earlier this month.

India’s generic drug manufacturers are also running to create cheap versions of Vejovi, which are in the dialect to grab a part of the weight-laoss market, which Nuwama’s analysts estimate that by 2035 will reach Rs 14.5 lakh crore in a year globally.

Novo can also monitor some industries, such as the market research firm, may have to pay more competitively in India in India.

The one-time-weekly injection approved by the drug regulator of India, the price of Maunjaro is Rs 4,375 for a 5 mg vial and Rs 3,500 for 2.5 mg vial, its lowest dose, the company told the Reuters. Its highest dose is 15 mg.

In India, a patient may have to spend around Rs 17,000 per month for taking a weekly dose of 5 mg under the doctor’s prescription.

Mounjaro holds a list of about Rs 93,000 per month in the US, although the amount that the patient pays depends largely on their insurance plan.

Zepbound, which has the same active ingredient, Tirzepatide, is the brand name for the American Weight-Loss version, in which Mounjaro is sold for diabetes there.

The lily provides a zipbound of 5 mg, 7.5 mg, and 10 mg vials, which is more for Rs 42,791 and for a month supply if customers pay cash payments without any third party participation.

An advisory endocrinologist Abhijeet Bhogaj said that Manipal Hospitals in Bangalore have seen an increase of more than 20% in the patient’s questions on the availability of weight loss drug.

In the increased interest, some doctors have urged patients to get more information before chlaning for medicine.

Hyderabad -based bariatric surgeon Amar Venapusa said, “Use requires extensive awareness about use.”

A few years ago, 32 -year -old Kerathi Reddy, who underwent biatric surgery, shot his first Maunjaro at the Clinic in Venapusa this week.

“My friends and family living abroad have already tried it and have seen good results,” Reddy told Reuters. “I am waiting for it to be available in India.”